Dabrafenib for the treatment of melanoma

Bibliography

• Cancer Facts and Figures 2014. American Cancer Society. Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/ [Last accessed 10 January 2015]
   Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
   PubMed Web of Science ®Google Scholar
• McDermott D, Lebbe C, Hodi FS, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 2014;40(9):1056-64
   PubMed Web of Science ®Google Scholar
• Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17(9):2745-51
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Eng J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17(7):2105-16
   PubMed Web of Science ®Google Scholar
• Jarkowski AIII, Norris L, Trinh VA. Controversies in the management of advanced melanoma: “gray” areas amid the “black and blue”. Ann Pharmacother 2014;48(11):1456-68
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380(9839):358-65
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Eng J Med 2012;366(8):707-14
   PubMed Web of Science ®Google Scholar
• Rahman MA, Salajegheh A, Smith RA, Lam AK. BRAF inhibitors: from the laboratory to clinical trials. Crit Rev Oncol Hematol 2014;90(3):220-32
   PubMed Web of Science ®Google Scholar
• Dummer CR, Nyakas M, Grant A, et al. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. J Clin Oncol 2014;31:suppl abstract 9028
   Google Scholar
• Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma (COLUMBUS). Available from: https://clinicaltrials.gov/ct2/show/NCT01909453?term=Study+Comparing+Combination+of+LGX818+Plus+MEK162+and+LGX818+Monotherapy&rank=1 [Last accessed 5 January 2015]
   Google Scholar
• Kefford R, RJ S, WH M, et al. Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results. J Translat Med 2014;12(Suppl 1):P5
   PubMedGoogle Scholar
• Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol 2010;80(5):624-37
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
   PubMed Web of Science ®Google Scholar
• Falchook GS, Long GV, Kurzrock R, et al. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 2014;20(17):4449-58
   PubMed Web of Science ®Google Scholar
• Ballantyne AD, Garnock-Jones KP. Dabrafenib: first global approval. Drugs 2013;73(12):1367-76
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information: Tafinlar (dabrafenib) capsules. FDA. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202806s002lbl.pdf [Last accessed 10 Janury 2015].
   Google Scholar
• Gentilcore G, Madonna G, Mozzillo N, et al. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer 2013;13:17
   PubMed Web of Science ®Google Scholar
• Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379(9829):1893-901
   PubMed Web of Science ®Google Scholar
• Trinh VA, Davis JE, Anderson JE, Kim KB. Dabrafenib therapy for advanced melanoma. Ann Pharmacother 2014;48(4):519-29
   PubMed Web of Science ®Google Scholar
• Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res 2014;20(7):1965-77
   PubMed Web of Science ®Google Scholar
• Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: where next for melanoma therapy? Br J Cancer 2015;112(2):217-26
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31(26):3205-11
   PubMed Web of Science ®Google Scholar
• Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13(11):1087-95
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22(11):2101-7
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Eng J Med 2012;367(18):1694-703
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. N Eng J Med 2015;372(1):30-9
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Eng J Med 2014;371(20):1877-88
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Eng J Med 2014;371(20):1867-76
   PubMed Web of Science ®Google Scholar
• Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma. Melanoma Institute Australia. Available from: https://clinicaltrials.gov/ct2/show/NCT01972347?term=Neoadjuvant+Dabrafenib+%2B+Trametinib+for+AJCC+Stage+IIIB-C+BRAF+V600&rank=1 [Last accessed 16 June 2015]
   Google Scholar
• Combi-Neo Study for Stage IIIB-C and Oligometastatic Stage IV Melanoma. M.D. Anderson Cancer Center. Available from: https://clinicaltrials.gov/ct2/show/NCT02231775?term=Combi-Neo+Study+for+Stage+IIIB-C+and+Oligometastatic+Stage+IV+Melanoma&rank=1 [Last accessed 16 June 2015]
   Google Scholar
• A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. (COMBI-AD). GlaxoSmithKline. Available from: https://clinicaltrials.gov/ct2/show/NCT01682083?term=A+Study+of+the+BRAF+Inhibitor+Dabrafenib+in+Combination+With+the+MEK+Inhibitor&rank=1 [Last accessed 16 June 2015]
   Google Scholar
• Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation. Memorial Sloan Kettering Cancer Center. Available from: https://clinicaltrials.gov/ct2/show/NCT01682213?term=Adjuvant+Dabrafenib+%28GSK2118436%29+in+Patients+With+Surgically+Resected+AJCC+Stage+IIIC&rank=1 [Last accessed 16 June 2015]
   Google Scholar
• Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012;167(5):1153-60
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15(3):323-32
   PubMed Web of Science ®Google Scholar
• Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep 2013;15(3):249-59
   PubMedGoogle Scholar
• Satzger I, Degen A, Asper H, et al. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol 2013;31(13):e220-2
   PubMed Web of Science ®Google Scholar
• Johnson DB, Flaherty KT, Weber JS, et al.et al. Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. J Clin Oncol 2014;32(33):3697-704
   PubMed Web of Science ®Google Scholar
• Tafinlar Capsules: Product Information. 2015. Novartis. Available from: http://www.google.com/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=5&ved=0CEMQFjAE&url=http%3A%2F%2Fwww.novartis.com.au%2FDownloadFile.aspx%3Ft%3Dp%26f%3Dtaf.pdf%26dateid%3D1434419833000&ei=P96BVfHiLsvh-QG8m4CACg&usg=AFQjCNHng2Zr6Qbb8_iHhTkKZ-b1FuDvKA [Last accessed 16 June 2015]
   Google Scholar
• Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma. GlaxoSmithKline. Available from: https://clinicaltrials.gov/ct2/show/NCT01767454?term=Study+of+Dabrafenib+%2B%2F-+Trametinib+in+Combination+With+Ipilimumab+for+V600E%2FK&rank=1 [Last accessed 22 May 2015]
   Google Scholar
• Puzanov I. Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) +/- the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma. J Translat Med 2015;13:Suppl 1:K8
   PubMed Web of Science ®Google Scholar